Keeping Up to Date with the Ever-Changing Face of Cancer Treatment

The recent news that KymriahTM (tisagenecleucel) has become the first chimeric antigen receptor T-cell (CAR-T) therapy to be approved by the US Food and Drug Administration (FDA) is a powerful reminder of the growing importance of immunotherapy in the fight against cancer. But while groundbreaking immunotherapy treatments like KymriahTM offer hope to patients with what […]

Read More…